Live
- Campaign ends for first phase of LS polls in Assam
- New features in TNEB Online payment: What has changed?
- BSE vs. NSE: Unveiling Key Differences and How They Impact Investors
- Financial Fluency, The Power of Punctual Tax Payments
- Dubai Food Festival kicks off This Week with Exciting Lineup of Gastronomic Events and Experiences for its Eleventh Edition
- KeyPoint Technologies Achieves Milestone with Indian Patent Office Approval for Contextual Discovery Innovation
- Unacademy Hosts Udaan in Vizag To Empower Thousands of IIT JEE and NEET UG Aspirants
- Chandrababu Naidu, Pawan Kalyan confident of 'Rama Rajyam' in Andhra
- Global Team Toyota Athletes from Asia Set to Reach for Greater Heights at Paris 2024
- Samsung Announces New Era of AI TVs in India, Launches Neo QLED 8K, Neo QLED 4K and OLED TVs with Powerful AI Features
Government clears Johnson's single-dose Covid vaccine
Johnson & Johnson Covid-19 vaccine
India has granted Emergency Use Authorisation (EUA) to US drug maker Johnson & Johnson’s single-dose Covid-19 vaccine, Union Health Minister Mansukh Mandaviya said on Saturday.
New Delhi: India has granted Emergency Use Authorisation (EUA) to US drug maker Johnson & Johnson's single-dose Covid-19 vaccine, Union Health Minister Mansukh Mandaviya said on Saturday.
"Johnson and Johnson's single-dose Covid-19 vaccine is given approval for Emergency Use in India. Now India has 5 EUA vaccines. This will further boost our nation's collective fight against COVID-19," Mansukh Mandaviya said in a tweet. In a statement, Johnson & Johnson said this is an important step forward in accelerating the availability of their Covid-19 vaccine to help end the pandemic.
"We are pleased to announce that on August 7, 2021, the Government of India issued Emergency Use Authorisation (EUA) for the Johnson & Johnson Covid-19 single-dose vaccine in India, to prevent Covid-19 in individuals 18 years of age and older," Johnson & Johnson's India spokesperson said in a statement.
So far, four vaccines have been given Emergency Use Authorisation (EUA) in India - AstraZeneca's Covishield, Covaxin, Sputnik V and Moderna. On August 5, Johnson & Johnson applied for Emergency Use Authorisation for its single-dose Covid vaccine in India. The US drug major claims that its vaccine, in clinical trials, proved to be 85 per cent effective in preventing severe disease. The vaccine also showed protection against the Delta variant and other emerging strains.
